National Institute on Drug Abuse/NIH SBIR/STTR Information

Did you know that the National Institute on Drug Abuse (NIDA) allocates more than twenty million dollars a year to support small businesses?
Unfortunately,  recent analysis revealed that no small business in the state of Indiana has received NIDA SBIR/STTR awards during the time frame from 2008-2014.
Are you contemplating obtaining funding to help with research leading to commercialization?
If you have an idea and would like to consider federal funding, we are available to speak with you regarding your research and how it can fit within NIDA’s mission and priorities. (http://www.drugabuse.gov/about-nida and http://grants.nih.gov/grants/guide/notice-files/NOT-DA-11-020.html)

We support:

1) Drug discovery and development-enabling activities: Development of innovative technologies, methods or tools, including but not limited to:

• Innovative in vitro, in situ, or in vivo tools for the molecular analysis of the central nervous system, normal and/or diseased.
• Tools to simplify drug design through the use of advanced computing (simulation) methods.
• Development of pre-clinical models for addiction.
• Novel analytical technologies and methods that develop the understanding of basic mechanisms of drug action and improve drug testing; technologies designed to overcome the performance restrictions of current drug discovery and development tools.
• Technologies, including molecular imaging, gene expression profiling, genotyping and sequencing approaches designed to better inform the diagnosis and treatment of substance use disorders

2) Drug discovery and clinical activities: Application of emerging and existing technologies and platforms to SUD drug development. Medical products with potential to minimize drug seeking, compulsive behavior, and/or addictive processes are strongly encouraged. Examples might include, but are not limited to:

• Chemistry / pharmaceutical drug development
• Formulation and/or enhanced delivery of drugs
• Preclinical and/or clinical drug advancement
• Development of biomarkers related to treatment outcomes
• Prescription drug prevention and services research
• Cultivate sensitive web-based/mobile-based behavioral programs to improve compliance, complement pharmacological treatments and expand treatment access for underserved populations

The NIDA SBIR/STTR Program is willing to help your efforts by working with you to frame the narrative and highlight the science that is of interest to NIDA, outline what NIDA wants to see in commercialization plans and provide background on how the proposal would be reviewed. The experts at NIDA would like to assist individuals and small businesses to apply for SBIR/STTR funding.

Please reach out to:
Elena Koustova, PhD, MBA
Director, Office of Translational Initiatives and Program Innovations (OTIPI),
NIDA SBIR/STTR Coordinator,
NIDA Challenge Manager,
National Institute on Drug Abuse (NIDA)
6001 Executive Blvd
Room 4286, MSC 9555
Bethesda, MD 20892-9555
Phone: (301) 496-8768
Fax: (301) 594-6043
Email: elena.koustova@nih.gov
koustovae@nida.nih.gov